Gyre Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Gyre Therapeutics has a total shareholder equity of $88.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $122.0M and $33.2M respectively. Gyre Therapeutics's EBIT is $20.6M making its interest coverage ratio -17.4. It has cash and short-term investments of $37.4M.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | -17.4x |
| Cash | US$37.35m |
| Equity | US$88.77m |
| Total liabilities | US$33.24m |
| Total assets | US$122.01m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: GYRE's short term assets ($62.7M) exceed its short term liabilities ($19.5M).
Long Term Liabilities: GYRE's short term assets ($62.7M) exceed its long term liabilities ($13.8M).
Debt to Equity History and Analysis
Debt Level: GYRE is debt free.
Reducing Debt: GYRE has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable GYRE has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: GYRE is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 110.4% per year.